Interleukin-10 concentration and coronary heart disease (CHD) event risk in the estrogen replacement and atherosclerosis (ERA) study

Atherosclerosis

Volumn 197, Issue 1, 2008, Pages 443-447

  Lakoski, Susan G ^a   Liu, Yongmei ^a   Brosnihan, K Bridget ^a   Herrington, David M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Coronary heart disease; Inflammation; Interleukin 10

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CYTOKINE; ESTROGEN; INTERLEUKIN 10; INTERLEUKIN 6;

AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE COURSE; ESTROGEN THERAPY; FEMALE; FOLLOW UP; HAZARD RATIO; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; INFLAMMATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PATHOGENESIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICAL ANALYSIS;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY DISEASE; DISEASE PROGRESSION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; MIDDLE AGED; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; VASCULITIS;

EID: 39449137843     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.06.033     Document Type: Article

References (23)

1. de Vries J.E. Immunosuppressive and anti-inflammatory properties of interleukin 10. Ann Med 27 5 (1995) 537-541
2. De Waal M.R., Abrams J., Bennett B., Figdor C.G., and de Vries J.E. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174 5 (1991) 1209-1220
3. + T cell clones and resting T cells Specific inhibition of IL-2 production and proliferation. J Immunol 150 11 (1993) 4754-4765
4. Jenkins J.K., Malyak M., and Arend W.P. The effects of interleukin-10 on interleukin-1 receptor antagonist and interleukin-1 beta production in human monocytes and neutrophils. Lymphokine Cytokine Res 13 1 (1994) 47-54
5. Rousset F., Garcia E., Defrance T., et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A 89 5 (1992) 1890-1893
6. + T cells. J Immunol 160 7 (1998) 3188-3193
7. Potteaux S., Esposito B., van Oostrom O., et al. Leukocyte-derived interleukin 10 is required for protection against atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 24 8 (2004) 1474-1478
8. Eefting D., Schepers A., De Vries M.R., et al. The effect of interleukin-10 knock-out and overexpression on neointima formation in hypercholesterolemic APOE*3-Leiden mice. Atherosclerosis (2006) 4
9. Satterthwaite G., Francis S.E., Suvarna K., et al. Differential gene expression in coronary arteries from patients presenting with ischemic heart disease: further evidence for the inflammatory basis of atherosclerosis. Am Heart J 150 3 (2005) 488-499
10. Mallat Z., Heymes C., Ohan J., et al. Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. Arterioscler Thromb Vasc Biol 19 3 (1999) 611-616
11. Huang Y., Li T., Sane D.C., and Li L. IRAK1 serves as a novel regulator essential for lipopolysaccharide-induced interleukin-10 gene expression. J Biol Chem 279 49 (2004) 51697-51703
12. Szodoray P., Timar O., Veres K., et al. TH1/TH2 imbalance, measured by circulating and intracytoplasmic inflammatory cytokines-immunological alterations in acute coronary syndrome and stable coronary artery disease. Scand J Immunol 64 3 (2006) 336-344
13. Herrington D.M., Reboussin D.M., Klein K.P., et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Control Clin Trials 21 3 (2000) 257-285
14. Herrington D.M., Reboussin D.M., Brosnihan K.B., et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 343 8 (2000) 522-529
15. Yamashita H., Shimada K., Seki E., Mokuno H., and Daida H. Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris. Am J Cardiol 91 2 (2003) 133-136
16. Smith D.A., Irving S.D., Sheldon J., Cole D., and Kaski J.C. Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation 104 7 (2001) 746-749
17. Nishihira K., Imamura T., Yamashita A., et al. Increased expression of interleukin-10 in unstable plaque obtained by directional coronary atherectomy. Eur Heart J 27 14 (2006) 1685-1689
18. Heeschen C., Dimmeler S., Hamm C.W., et al. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 107 16 (2003) 2109-2114
19. Singh U., Devaraj S., Dasu M.R., et al. C-reactive protein decreases interleukin-10 secretion in activated human monocyte-derived macrophages via inhibition of cyclic AMP production. Arterioscler Thromb Vasc Biol 26 11 (2006) 2469-2475
20. Kumada M., Kihara S., Ouchi N., et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 109 17 (2004) 2046-2049
21. Lee M.S., Mueller R., Wicker L.S., Peterson L.B., and Sarvetnick N. IL-10 is necessary and sufficient for autoimmune diabetes in conjunction with NOD MHC homozygosity. J Exp Med 183 6 (1996) 2663-2668
22. Moritani M., Yoshimoto K., Tashiro F., et al. Transgenic expression of IL-10 in pancreatic islet A cells accelerates autoimmune insulitis and diabetes in non-obese diabetic mice. Int Immunol 6 12 (1994) 1927-1936
23. + T and B lymphocytes. J Immunol 161 8 (1998) 4420-4427